JP7881475B2 - Cas12i2変異体ポリペプチドを含む組成物及びその使用 - Google Patents

Cas12i2変異体ポリペプチドを含む組成物及びその使用

Info

Publication number
JP7881475B2
JP7881475B2 JP2022560154A JP2022560154A JP7881475B2 JP 7881475 B2 JP7881475 B2 JP 7881475B2 JP 2022560154 A JP2022560154 A JP 2022560154A JP 2022560154 A JP2022560154 A JP 2022560154A JP 7881475 B2 JP7881475 B2 JP 7881475B2
Authority
JP
Japan
Prior art keywords
cas12i2
polypeptide
mutant
composition
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022560154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520504A5 (cg-RX-API-DMAC7.html
JP2023520504A (ja
Inventor
シャオロン ショーン,
ブレンダン, ジェイ ヒルバート,
クイントン, ノーマン ウェッセルズ,
ノア, マイケル ジャカイモ,
ロイ ジブラット,
ジェイソン, マイケル カート,
ティア, マリー ディドマッソ,
ジェフリー, レイモンド ハスウェル,
アンソニー, ジェームス ギャリティ,
コリン, アレクグザンダー マッガァ,
デイヴィッド, エー. スコット,
デレク, マイケル セルキオン,
Original Assignee
アーバー バイオテクノロジーズ, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーバー バイオテクノロジーズ, インコーポレイテッド filed Critical アーバー バイオテクノロジーズ, インコーポレイテッド
Publication of JP2023520504A publication Critical patent/JP2023520504A/ja
Publication of JP2023520504A5 publication Critical patent/JP2023520504A5/ja
Application granted granted Critical
Publication of JP7881475B2 publication Critical patent/JP7881475B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022560154A 2020-03-31 2021-03-31 Cas12i2変異体ポリペプチドを含む組成物及びその使用 Active JP7881475B2 (ja)

Applications Claiming Priority (37)

Application Number Priority Date Filing Date Title
US202063002999P 2020-03-31 2020-03-31
US202063003090P 2020-03-31 2020-03-31
US202063003064P 2020-03-31 2020-03-31
US63/003,064 2020-03-31
US63/003,090 2020-03-31
US63/002,999 2020-03-31
US202063012007P 2020-04-17 2020-04-17
US63/012,007 2020-04-17
US202063026277P 2020-05-18 2020-05-18
US202063026562P 2020-05-18 2020-05-18
US202063026606P 2020-05-18 2020-05-18
US202063026523P 2020-05-18 2020-05-18
US63/026,277 2020-05-18
US63/026,606 2020-05-18
US63/026,562 2020-05-18
US63/026,523 2020-05-18
US202063063831P 2020-08-10 2020-08-10
US202063063819P 2020-08-10 2020-08-10
US202063063859P 2020-08-10 2020-08-10
US202063063879P 2020-08-10 2020-08-10
US63/063,859 2020-08-10
US63/063,879 2020-08-10
US63/063,819 2020-08-10
US63/063,831 2020-08-10
US202063085895P 2020-09-30 2020-09-30
US202063085862P 2020-09-30 2020-09-30
US202063085752P 2020-09-30 2020-09-30
US202063085792P 2020-09-30 2020-09-30
US63/085,895 2020-09-30
US63/085,792 2020-09-30
US63/085,862 2020-09-30
US63/085,752 2020-09-30
US202163147968P 2021-02-10 2021-02-10
US202163147850P 2021-02-10 2021-02-10
US63/147,968 2021-02-10
US63/147,850 2021-02-10
PCT/US2021/025257 WO2021202800A1 (en) 2020-03-31 2021-03-31 Compositions comprising a cas12i2 variant polypeptide and uses thereof

Publications (3)

Publication Number Publication Date
JP2023520504A JP2023520504A (ja) 2023-05-17
JP2023520504A5 JP2023520504A5 (cg-RX-API-DMAC7.html) 2024-04-11
JP7881475B2 true JP7881475B2 (ja) 2026-06-29

Family

ID=75640000

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560154A Active JP7881475B2 (ja) 2020-03-31 2021-03-31 Cas12i2変異体ポリペプチドを含む組成物及びその使用

Country Status (12)

Country Link
US (1) US20230332119A1 (cg-RX-API-DMAC7.html)
EP (1) EP4127154A1 (cg-RX-API-DMAC7.html)
JP (1) JP7881475B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230009379A (cg-RX-API-DMAC7.html)
CN (2) CN115698278B (cg-RX-API-DMAC7.html)
AU (1) AU2021249119A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019713A2 (cg-RX-API-DMAC7.html)
CA (1) CA3177749A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022015170A2 (cg-RX-API-DMAC7.html)
IL (1) IL296791A (cg-RX-API-DMAC7.html)
MX (1) MX2022012189A (cg-RX-API-DMAC7.html)
WO (1) WO2021202800A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US20230193243A1 (en) * 2020-05-29 2023-06-22 Arbor Biotechnologies, Inc. Compositions comprising a cas12i2 polypeptide and uses thereof
EP4237557A1 (en) * 2020-10-30 2023-09-06 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting pdcd1 and uses thereof
TW202246497A (zh) * 2021-01-20 2022-12-01 美商阿伯生物技術公司 Cas12i2融合分子及其用途
AU2022284804A1 (en) * 2021-06-01 2023-12-07 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
KR20240034746A (ko) 2021-06-04 2024-03-14 아버 바이오테크놀로지스, 인크. 하이드록시산 산화효소 1(hao1)을 표적으로 하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
WO2022256655A2 (en) 2021-06-04 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting lactate dehydrogenase a (ldha) and uses thereof
US20220396782A1 (en) 2021-06-04 2022-12-15 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting transthyretin (ttr) and uses thereof
KR20240052763A (ko) * 2021-08-11 2024-04-23 아버 바이오테크놀로지스, 인크. 스타스민 2 (stmn2)를 표적화하는 rna 가이드를 포함하는 유전자 편집 시스템 및 이의 용도
WO2023018856A1 (en) 2021-08-11 2023-02-16 Arbor Biotechnologies, Inc. Gene editing systems comprising an rna guide targeting polypyrimidine tract binding protein 1 (ptbp1) and uses thereof
WO2023034475A1 (en) 2021-09-01 2023-03-09 Arbor Biotechnologies, Inc. Cells modified by a cas12i polypeptide
EP4399293A4 (en) * 2021-09-10 2025-10-15 Arbor Biotechnologies Inc COMPOSITIONS COMPRISING A CAS12I POLYPEPTIDE AND USES THEREOF
AU2022382751A1 (en) * 2021-11-02 2024-05-23 Huidagene Therapeutics (Singapore) Pte. Ltd. Novel crispr-cas12i systems and uses thereof
WO2023081377A2 (en) * 2021-11-05 2023-05-11 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting ciita and uses thereof
WO2023122433A1 (en) 2021-12-22 2023-06-29 Arbor Biotechnologies, Inc. Gene editing systems targeting hydroxyacid oxidase 1 (hao1) and lactate dehydrogenase a (ldha)
WO2023138685A1 (en) * 2022-01-24 2023-07-27 Huidagene Therapeutics Co., Ltd. Novel crispr-cas12i systems and uses thereof
EP4514954A4 (en) * 2022-04-25 2026-03-25 Huidagene Therapeutics Singapore Pte Ltd NEW CRISPR-CAS12I SYSTEMS AND THEIR USES
EP4627083A1 (en) 2022-11-30 2025-10-08 Arbor Biotechnologies, Inc. Reverse transcriptase-mediated genetic editing of transthyretin (ttr) and uses thereof
US20260232844A1 (en) 2023-02-15 2026-08-13 Arbor Biotechnologies, Inc. Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
WO2025096594A2 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof
CN117431235A (zh) * 2023-11-06 2024-01-23 微光基因(苏州)有限公司 CRISPR-Cas系统及其应用
WO2025147604A1 (en) 2024-01-05 2025-07-10 Arbor Biotechnologies, Inc. Methods for treating primary hyperoxaluria via genetic editing of hydroxyacid oxidase 1
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such
CN120424908B (zh) * 2025-07-10 2025-09-12 南京农业大学 一种基于LAMP与CRISPR/Cas的检测方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201707569YA (en) 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
WO2014204725A1 (en) * 2013-06-17 2014-12-24 The Broad Institute Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
EP3924479A4 (en) * 2019-02-13 2023-01-25 Beam Therapeutics, Inc. ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE
WO2024178144A1 (en) * 2023-02-22 2024-08-29 Prime Medicine, Inc. Methods and compositions for editing nucleotide sequences

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019178427A1 (en) 2018-03-14 2019-09-19 Arbor Biotechnologies, Inc. Novel crispr dna targeting enzymes and systems

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Nature Communications,2020年,11:5241,pp.1-14
Science,2019年,Vol.363,pp.88-91

Also Published As

Publication number Publication date
KR20230009379A (ko) 2023-01-17
BR112022019713A2 (pt) 2022-12-20
WO2021202800A1 (en) 2021-10-07
IL296791A (en) 2022-11-01
CN115698278B (zh) 2025-10-17
CN121380024A (zh) 2026-01-23
CO2022015170A2 (es) 2022-11-08
CN115698278A (zh) 2023-02-03
MX2022012189A (es) 2023-01-05
US20230332119A1 (en) 2023-10-19
CA3177749A1 (en) 2021-10-07
AU2021249119A1 (en) 2022-10-20
EP4127154A1 (en) 2023-02-08
JP2023520504A (ja) 2023-05-17

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260227

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20260227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260519

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260617

R150 Certificate of patent or registration of utility model

Ref document number: 7881475

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150